Missouri is set to get a chunk of cash as part of a settlement involving the maker of EpiPens.
Mylan will pay Missouri more than $3 million. Overall, the company will have to pay $465 million after being accused of falsely classifying EpiPens as generic drugs. That means the company under-paid rebates owed to the state of Missouri for Medicaid payments.
Copyright 2017 KMOV (Meredith Corporation). All rights reserved